| __timestamp | Bristol-Myers Squibb Company | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 4534000000 | 46425000 |
| Thursday, January 1, 2015 | 5920000000 | 81491000 |
| Friday, January 1, 2016 | 4940000000 | 94291000 |
| Sunday, January 1, 2017 | 6411000000 | 121827000 |
| Monday, January 1, 2018 | 6345000000 | 160524000 |
| Tuesday, January 1, 2019 | 6148000000 | 200000000 |
| Wednesday, January 1, 2020 | 11143000000 | 275000000 |
| Friday, January 1, 2021 | 10195000000 | 328100000 |
| Saturday, January 1, 2022 | 9509000000 | 463800000 |
| Sunday, January 1, 2023 | 9299000000 | 565000000 |
| Monday, January 1, 2024 | 11159000000 | 731100000 |
Cracking the code
In the ever-evolving landscape of pharmaceuticals, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Bristol-Myers Squibb Company and Neurocrine Biosciences, Inc. have demonstrated contrasting yet significant investment strategies in R&D.
Bristol-Myers Squibb, a global biopharmaceutical leader, has consistently increased its R&D expenses, peaking in 2020 with a 150% rise from 2014. This surge underscores their dedication to pioneering treatments and maintaining a competitive edge. Meanwhile, Neurocrine Biosciences, a smaller yet dynamic player, has shown a remarkable 1,100% increase in R&D spending over the same period, reflecting its aggressive pursuit of innovative solutions in neurology and endocrinology.
These trends highlight the diverse strategies within the industry, where both giants and niche companies are investing heavily to drive future breakthroughs.
Who Prioritizes Innovation? R&D Spending Compared for Amgen Inc. and Bristol-Myers Squibb Company
Bristol-Myers Squibb Company vs Gilead Sciences, Inc.: Strategic Focus on R&D Spending
R&D Insights: How Bristol-Myers Squibb Company and Zoetis Inc. Allocate Funds
Bristol-Myers Squibb Company or BeiGene, Ltd.: Who Invests More in Innovation?
Selling, General, and Administrative Costs: Bristol-Myers Squibb Company vs Neurocrine Biosciences, Inc.
Comparing Innovation Spending: Bristol-Myers Squibb Company and Dr. Reddy's Laboratories Limited
Research and Development: Comparing Key Metrics for Bristol-Myers Squibb Company and Alkermes plc
Comparing Innovation Spending: Bristol-Myers Squibb Company and PTC Therapeutics, Inc.
Comparing Innovation Spending: Bristol-Myers Squibb Company and Catalyst Pharmaceuticals, Inc.
Bristol-Myers Squibb Company vs Perrigo Company plc: Strategic Focus on R&D Spending
R&D Insights: How Neurocrine Biosciences, Inc. and Corcept Therapeutics Incorporated Allocate Funds
Research and Development Investment: Neurocrine Biosciences, Inc. vs MorphoSys AG